A vs. NTRA: Agilent vs. Natera Stock Comparison
How do Agilent (A) and Natera (NTRA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and Natera (NTRA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while NTRA is classified in Biotechnology.
| Profile Item | A | NTRA |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | Natera, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 49.28 billion USD | 45.05 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 18, 1999 | July 1, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | NTRA |
|---|---|---|
| Total Return (1Y) | 22.92% | 61.03% |
| Total Return (3Y, Annualized) | 19.33% | 92.02% |
| Total Return (5Y, Annualized) | 3.03% | 23.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | NTRA |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 52.30% |
| Beta (5Y) | 1.22 | 1.58 |
| Max Drawdown (5Y) | -38.09% | -75.72% |
| Avg. Volume (3M) | 2.25M | 1.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | NTRA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 1.09 |
| Sortino Ratio (1Y) | 0.96 | 1.63 |
Profitability
ROE (TTM)
Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Agilent (A) reports 20.97%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Agilent (A) reports 19.53%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Agilent (A) reports 25.56%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | NTRA |
|---|---|---|
| ROE (TTM) | 20.97% | -10.55% |
| ROA (TTM) | 8.63% | -6.79% |
| Net Margin (TTM) | 19.53% | -5.66% |
| Operating Margin (TTM) | 25.56% | -7.64% |
| Gross Margin (TTM) | 53.65% | 65.14% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.
Growth Metrics
| Metric | A | NTRA |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 35.90% |
| Revenue Growth (3Y CAGR) | 0.48% | 41.14% |
| EPS Growth (YoY) | 3.16% | -- |
| EPS Growth (3Y CAGR) | 3.02% | -- |
Financial Strength
Current Ratio (MRQ)
Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | NTRA |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 2.81 |
| Debt / Equity (MRQ) | 0.56 | 0.13 |
| Net Debt / EBITDA | 1.15 | -- |
Dividends
Dividend Yield (TTM)
Natera (NTRA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Natera (NTRA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 19.98% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Agilent (A) trades at 34.47 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
P/S Ratio (TTM)
On P/S ratio, both Agilent (A) at 6.68 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Agilent (A) at 6.69 sits in the upper P/B ratio quartile, and Natera (NTRA) at 23.99 prices even higher, above its industry range.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | NTRA |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | -- |
| P/S Ratio (TTM) | 6.68 | 15.49 |
| P/B Ratio (MRQ) | 6.69 | 23.99 |
| Free Cash Flow Yield (TTM) | 2.15% | 0.19% |